BioWorld

April 27, 2004

Tarceva Trial Proves Positive, Pushes OSI, Genentech Stocks

Investors adored results from a Phase III trial of an experimental cancer drug, significantly driving up stock prices of two of the companies involved in its development. (BioWorld Today) Read More

CV Therapeutics Begins Second Phase III Trial Of Regadenoson

Antisoma's Stock Falls On Phase III Miss With R1549

BioWorld Biotechnology State of the Industry Report 2004 now available

Advancing Three Cancer Drugs, Salmedix Takes Aim At $86M IPO

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 9, 2026.

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

BioWorld

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...